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The National Blood Group Reference Laboratory (NBGRL) in Israel
was established in Jerusalem in 1971 and transferred to Magen
David Adom (MDA), National Blood Services in 1995. This
laboratory was the inspiration of the first author of this article for
over 30 years. The realization of this vision was made possible by
the cooperation of colleagues and laboratory workers in blood
transfusion services throughout the country. The aim of the service
was to provide diagnostic help in resolving immunohematologic
problems found in the blood banks and clinics in Israel. In the
beginning, only a part-time technician performed the work and
testing was done using very limited reagents. The service was
expanded by personal visits to all of the 22 blood banks in Israel to
explain the aim of this new service and to educate them about the
importance of resolving each and every case. One major issue was
the cost involved in referring problems but it was decided at the
outset that these would be covered by the government to ensure
that a workup would be performed for all referred cases. The
expansion of the service could not have been achieved without the
help of the SCARF program. This voluntary service enabled us to
identify the first rare donors in Israel, resolve complex cases, and
find compatible blood for our patients. To illustrate the importance
of the NBGRL in Israel and the rapid resolution of cases referred,
several individual stories are described. The purpose of this review
is to show the importance of the NBGRL in identifying rare blood
groups and in providing and coordinating services and the
importance of keeping in close contact with the rare donors to
encourage and promote their donations, which may save lives.
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The Gerbich (Ge) Story
Two of the earliest samples that we received from
SCARF were from a donor whose RBCs were Ge:–2,3
(Yus phenotype) with anti-Ge2 in the serum and a
donor whose RBCs were Ge:–2,–3 (Gerbich
phenotype) with anti-Ge2,3 in the serum.
In 1976, a sample from a Jewish blood donor (ZY)
born in Iraq, whose ABO blood group could not be
resolved, was referred from Magen David Adom (MDA)
National Blood Services. This donor had never been
transfused and no antibodies had been detected in his
serum in previous donations. His RBCs typed as group
A, D+ and the serologic workup demonstrated the
presence of an antibody in his serum directed at a high-
incidence antigen. The RBCs of the donor were
subsequently shown to be Ge:–2,3 (Yus phenotype)
and his serum contained anti-Ge2. These findings were
proved using reagents provided by SCARF. They were
confirmed at that time by overseas laboratories
including that of the Medical Research Council Blood
Group Unit (MRC BGU) in London,then directed by Dr.
Ruth Sanger. The family of this donor was examined
and it was found that the donor was married to a first
cousin whose RBCs were shown to be Ge:2,3,4.
However, three of his children were found to be
Ge:–2,3 like him. The propositus was employed as a
mounted policeman in Jerusalem and was frequently
seen riding on his white horse by the staff of the
laboratory where the diagnosis of his rare blood was
established. Because of the potential injury involved in
his work, it was decided to relocate him within the
service to a more sedentary position. However, the
donor later decided that he wished to return to his post
working with the horses in spite of the risks involved.
He and one of his sons became regular donors and
their units were frozen in MDA for future use. When
this son moved to live in the United States, he
continued to donate blood there.
In subsequent years, 20 other cases of donors with
anti-Ge2 were seen in our laboratory (Table 1); most of
them were found in Jews who emigrated from Ethiopia
and in Israeli Arabs. In the Ethiopian Jews in Israel, the
Yus phenotype (Ge:–2,3,4) was found and the
frequency of RBCs with the Ge:–2,3 phenotype may
reach 0.015 to 0.1 percent.1,2 Only two cases of donors
with Gerbich phenotype Ge:–2,–3,4 were found, in
one family who emigrated from Iraq.
We have not succeeded in convincing the other
Gerbich negative individuals to become regular donors
despite numerous letters, telephone calls, and even an
invitation to the rare blood meeting, which we will
describe later.
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The JMH Story
Over the years, the National Blood Group
Reference Laboratory (NBGRL) in Israel has identified
five samples of blood that appeared to be JMH–. Two
of these samples were subsequently found to be JMH
variants (Table 2).
In 1980, a woman (MR) was admitted for surgery.
An antibody directed at a high-incidence antigen was
identified in her serum and no compatible blood units
were found for transfusion. Additional testing at the
NBGRL showed that this antibody did not react with
enzyme (ficin)-treated RBCs. The identity of this
antibody could not be established in our service. The
RBCs of the patient reacted with anti-JMH. Samples of
blood from this woman were sent to several overseas
laboratories and an immediate reply was received from
the former Gamma Biologicals, Inc., Consultation and
Education Services (headed by Marilyn and John
Moulds), notifying us that the antibody maker had a
JMH variant phenotype. The RBCs of MR reacted with
known anti-JMH but her serum did not react with
known JMH– RBCs. Family screening identified a
brother of the same ABO group and of the same JMH
variant, so he could have been a potential donor if
blood had been required for the surgery. This Jewish
family immigrated to Israel from Poland. JMH variant
antibodies are not considered to be clinically
significant.3
Some time after this JMH variant (which was called
MR)4 was found, an additional JMH variant was
examined in a patient who had a terminal illness. This
variant was identified as being the same variant as that
found on the RBCs of MR. This patient was also a Polish
Jewish immigrant.
Many years later Dr. Axel Seltsam described the
molecular background that underlies the molecular
basis of the JMH variants.5
The pp (Tj[a–]) Story
The first finding of a rare blood group in the
NBGRL in Jerusalem, which proved to be the pp
phenotype, was in 1972.6 The blood was from a
woman who had been hospitalized for bleeding after a
miscarriage. The referring laboratory told us that the
RBC typings of the patient tested as group B but the
back tests “caused problems!” All RBCs (groups A, B,
and O) were agglutinated and, within a short period,
these RBCs hemolyzed in tube tests. We had never seen
a blood specimen from a pp phenotype patient but this
story sounded as though this was the problem.
Fortunately,no immediate transfusion was required and
the blood specimen was referred to the International
Blood Group Reference Laboratory (IBGRL) in the
United Kingdom for confirmation. Just before we
received the answer to confirm these suspicions, the
Table 1. The Gerbich negative phenotype in Israel
Reason for Country Gerbich Gerbich
Number referral Sex birth/origin groups antibodies
1a Blood donor M Iraq Ge:–2,3 anti-Ge2
1b Family screening M Israel Ge:–2,3 No antibody
1c Family screening F Israel Ge:–2,3 No antibody
1d Family screening F Israel Ge:–2,3 No antibody
2 Pregnancy F Ethiopia Ge:–2,3 anti-Ge2
3 Pregnancy F Ethiopia Ge:–2,3 anti-Ge2
4 Blood donor M Ethiopia Ge:–2,3 anti-Ge2
5a Pregnancy F Ethiopia Ge:–2,3 anti-Ge2
5b Family screening F Ethiopia Ge:–2,3 anti-Ge2
6a Pretransfusion F Iraq Ge:–2,–3,4 anti-Ge2
6b Family screening F Iraq Ge:–2,–3,4 No antibody
7 Pretransfusion F Ashkenazi Ge:–2,3 anti-Ge2
8 Donor screening F Ethiopia Ge:–2,3 No antibody
9 Pregnancy F Ethiopia Ge:–2,3 anti-Ge2
10 Pretransfusion F Iran Ge:–2,3 anti-Ge2
11 Pregnancy F Ethiopia Ge:–2,3 anti-Ge2
12a Pretransfusion F Israeli Arab Ge:–2,3 anti-Ge2
12b Family screening F Israeli Arab Ge:–2,3 anti-Ge2
13 Blood donor M Israeli Arab Ge:–2,3 anti-Ge2
14 Blood donor M Israeli Arab Ge:–2,3 anti-Ge2
15a Pregnancy F Ethiopia Ge:–2,3,4 anti-Ge2
15b Family and F Ethiopia Ge:–2,3,4 anti-Ge2
pregnancy
16a Pretransfusion M Israeli Arab Ge:–2,3 anti-Ge2
16b Family screening M Israeli Arab Ge:-2 No antibody
17 Dialysis F Ethiopia Ge:–2,3 anti-Ge2
18 Pretransfusion M Israeli Arab Ge:–2,3 anti-Ge2
19a Pregnancy F Israeli Arab Ge:–2,3 anti-Ge2
19b Family F Israeli Arab Ge:–2,3 No antibody
19c Family F Israeli Arab Ge:–2,3 anti-Ge2
19d Family M Israeli Arab Ge:–2,3 anti-Ge2
20 Blood donor M Israeli Arab Ge:–2,3 anti-Ge2
Table 2. The JMH variants in Israel
Reason for Country JMH JMH
Number referral Sex birth/origin groups antibodies
1a Pretransfusion F Poland JMH Anti-JMH
variant variant (MR)
1b Family screening M Poland JMH Anti-JMH
variant variant (MR)
2 Pretransfusion M Poland JMH Anti-JMH
variant variant (MR)
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patient was interviewed and she told the following
story: She had previously been admitted to another
hospital when she bled on a number of occasions in
the first trimester of her pregnancies. She had only one
live child. The previous hospital had told the patient
that they were unable to find compatible blood for her
and if she was readmitted and hemorrhaged she might
die!  On questioning the woman further, two important
findings emerged. She had a sister living in Israel, who
had the same obstetric history and who nearly died
after a transfusion. She also told us that she had a
cousin living in Israel who was said to have a rare blood
type. We were able to follow up with this latter relative
and we found that her blood had previously been
referred to the MRC BGU, at that time directed by Rob
Race, where her blood was found to be group AB, pp.7
A small sample of serum from this patient had been
stored in a freezer of the referring laboratory and the
RBCs of our patient did not react with this serum!  The
following day we received the confirmation from the
IBGRL in the United Kingdom and they arranged for
two units of blood to be sent from Umea, Sweden, for
our patient. These donors, who were twins, were
found in a dance hall and they immediately donated
their blood to be dispatched. A few years later, a
Swedish newspaper heard this story and decided to
bring the recipient and these donors together. The
donors were flown to Jerusalem and the recipient
arranged a party for them. The group met and
communicated with the help of translators.
As soon as our patient was well enough, she began
to donate her blood for freezing and she has donated
regularly nearly every 3 months. Here was a great
ending to a difficult problem. This lady told us, more
than once, that after her blood group had been
determined and she donated her blood for freezing, she
could now go to bed and sleep easily without any worry
of what might happen if she ever needed a transfusion.
Our second example of pp phenotype blood was
found in a blood donor. He was group AB but
unfortunately we were never able to follow up on this
young man. It turned out that he had been adopted
and did not want to know more relating to his rare
blood group and we lost track of him.
The next family turned out to be very special.8 This
patient was being prepared for a cesarean section and
no blood could be found for her. Her blood typed as
group B, D+, pp. This was the same blood group as our
first patient and it was agreed that some of the frozen
units of our first patient would be available if needed.
This new patient also had a history of numerous
miscarriages and no live child.
Immediately, the family was investigated and two
siblings were found to have RBCs of the pp phenotype.
Her brother was group B and her sister was group O.
The patient required transfusion, as she had a placenta
accreta, and, after delivery of a healthy baby, had to
have a hysterectomy. At that time she received one unit
donated by her brother. The baby soon developed
HDN and needed an exchange transfusion. The sister
of the proposita was group O and her blood was used
for the exchange transfusion for the baby.
The story relating to the sister was equally
interesting.9 This woman wanted to have a child but
she was unable to continue her pregnancies past the
first trimester: a classic story for a woman whose RBCs
were of the pp phenotype. For a number of years, this
woman called to inquire if any advances to help her
have a child were known. The situation was critical for
her and for her marriage, as both parents wanted to
have children. One day, the patient called saying that
she had heard on a midnight radio newscast that a
woman in a hospital in Baltimore (who had a story
similar to hers) had just delivered her first live child
and she wanted to know if this advance could be
applied to her situation. Dr. Paul Ness in Baltimore was
immediately approached and, indeed, his patient had a
similar blood group. With regular plasmapheresis as an
inpatient, she was able to continue the pregnancy past
the first trimester and she delivered a live child. The
protocol used in Baltimore was performed on our
patient at the Rambam Medical Center in Haifa, Israel.
There were many problems but the patient finally
delivered a live, healthy, full-term child who is now a
young adult. The meaning of the name of the doctor
who had engineered the treatment of the case in
Baltimore, Dr.“Ness,” in Hebrew translates as “miracle,”
and for our patient the birth of her child was indeed a
miracle.
This story is special in that any transfusion
problems in the family were overcome by the
cooperation of the siblings. These three siblings have
continued to donate their blood for storage in our
frozen blood bank.
Over the following years we continued to see more
cases of individuals who were of the special group pp.
We noted that a great percentage of these patients
were immigrants from North Africa, especially from
Morocco, where the frequency of the pp phenotype
reaches 1 in 55,663.10
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The Anti-Vel Story 
The first example of anti-Vel, sent to us in 1976,was
in the serum of a pregnant woman who had been
admitted to a local hospital for delivery. The hospital
was unable to find compatible blood for her before the
delivery. The specimen arrived in the NBGRL on a
Friday and the urgency for an answer meant that the
staff had to stay on to find a solution. We were doubtful
that we could solve this case but in the middle of the
night we found one last rare RBC sample from SCARF
in our collection that lacked the high-incidence antigen
Vel. To our surprise, this RBC sample was compatible
with the serum of this patient. At that time, there was
no blood in Israel and no known blood donors whose
RBCs were Vel–. As this woman was near term, the
decision was made with the blood bank director and
the gynecologists to take an autologous unit from the
patient and, after a few days, to take a second unit
before her delivery. Near the end of the first donation
the patient did not feel well and we positioned her in
the Trendelenburg position, only to find that this did
not really help her. We realized almost immediately
that, in this position, the uterus was pressing on her
chest, restricting her air entry, and so we reversed the
position. At once the patient felt well and the
phlebotomy of the blood unit was completed
successfully.11
Through the WHO International Rare Donor Panel
in the United Kingdom, we contacted the Red Cross
Blood Bank in Toronto, Canada, and arranged to have
two units of this rare blood shipped to Israel.
Fortunately, the woman delivered a healthy baby and
she only received her own predonated blood units.
One first cousin was found to be Vel– in the family
investigation.
Three additional examples of anti-Vel have been
seen over the years and hemolysis was seen with
enzyme (ficin)-treated RBCs in all of them.
The Cartwright (Yt) Story
The following summary of the Yt blood group
shows how the NBGRL must look out for findings that
could have bearing on the distribution of any particular
blood group and consider the value of investigating
them in the population.
Anti-Yta was first detected in the NBGRL in
Jerusalem in 1974. Over the subsequent 12-year
period,14 people who had anti-Yta in their serum were
found among 4470 referrals. This frequency of 1 in 320
was considered much higher than would have been
expected. To investigate the Yta and Ytb frequencies in
Israel, anti-Yta and anti-Ytb reagents were required. Anti-
Yta was available but we needed a supply of anti-Ytb. A
sample of anti-Ytb was offered by Marilyn and John
Moulds, which enabled the testing of the Yt groups of
Israeli Jews, Arabs, and Druze. These tests showed a
high frequency of the Ytb allele, which explained the
relatively high frequency of samples with anti-Yta in our
population. The Ytb allelic frequencies ranged between
0.1005 and 0.1522 in the Jewish communities and
were 0.1294 and 0.1429 in the Arab and Druze
communities, respectively.12,13 These are the highest
Ytb allelic frequencies observed so far in any
population tested,4 which explains why anti-Yta is the
most frequently detected antibody directed at a high-
incidence antigen in the NBGRL.
In retrospect, it is interesting that the late Dr.
Lyndall Molthan (in a written communication) had
written that she considered anti-Yta as “The Jewish
Connection”!
First Rare Blood Donor Meeting
For many years,we considered setting up a meeting
of our rare blood donors with the staff of the NBGRL;
this finally took place in April 2002. A special program
was prepared and invitations sent out. The venue was
the MDA National Blood Services and the attendance
far exceeded our expectations, showing us that our
rare donors understood the importance of this
gathering. Each person was registered and received a
badge and a folder of detailed information about their
blood group. Also included was a request to give
permission to be listed on the International Rare Donor
Panel managed by the IBGRL in the United Kingdom,to
which 43 donors agreed. The meeting began with
refreshments to enable the mingling of donors and
staff. The more formal program included lectures and
active participation of a number of individual rare
donors to talk about their personal stories and
problems. Throughout the whole meeting our donor
room remained open for the rare blood donors and
their families to donate. Thirty-two rare donors
donated blood and 15 samples were drawn from family
members for testing.14
Today, we have 566 registered rare blood donors,
some unique in the world, and more than 1200 frozen
units of rare blood are stored in high glycerol solution
in freezers at –80°C.
Our beginnings were modest. The service was
started in one small room with one physician and one
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laboratory worker employed for half of a day. We began
with minimal reagents, test tubes, and racks; a simple
centrifuge; a refrigerator; and one freezer. It did not
take us long to realize how many rare blood groups
came to light. This is certainly due to the ingathering
of the exiles to Israel from a multitude of different
ethnic backgrounds. Clearly, there has been a necessity
for additional help for the NBGRL in Israel. This help
has always been willingly extended by SCARF and by
many colleagues and laboratories all over the world;
they examine referred samples of blood and give their
advice. If we tried to list and thank all we would surely
leave some out, but we do want to mention and thank
Marilyn and John Moulds from the former Gamma
Biologicals, Inc.; the then MRC BGU in London directed
by the late Rob Race and Ruth Sanger and by Patricia
Tippett; and the WHO IBGRL in the United Kingdom,
managed by Carolyn Giles and later by Joyce Poole and
Marion Reid from the New York Blood Center. Their
help has proved invaluable to us, to the patients, and to
the field of immunohematology in general.
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